Generation Bio Co. (NASDAQ:GBIO) Receives Average Recommendation of “Hold” from Brokerages

Generation Bio Co. (NASDAQ:GBIO) has earned an average rating of “Hold” from the seven research firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $8.8750.

GBIO has been the subject of several analyst reports. Wedbush set a $5.50 target price on Generation Bio and gave the stock an “outperform” rating in a research note on Tuesday, December 16th. Jefferies Financial Group lowered shares of Generation Bio from a “buy” rating to a “hold” rating and cut their price objective for the company from $11.00 to $5.00 in a research report on Tuesday, December 16th. Citigroup reaffirmed a “market perform” rating on shares of Generation Bio in a report on Wednesday, December 17th. Needham & Company LLC reissued a “buy” rating and issued a $15.00 price target on shares of Generation Bio in a report on Friday, November 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Generation Bio in a report on Thursday, January 22nd.

Institutional Investors Weigh In On Generation Bio

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Seven Fleet Capital Management LP bought a new stake in Generation Bio during the fourth quarter valued at approximately $31,000. AQR Capital Management LLC purchased a new stake in shares of Generation Bio during the 1st quarter valued at $36,000. Marshall Wace LLP bought a new stake in shares of Generation Bio during the 2nd quarter worth $37,000. Y Intercept Hong Kong Ltd purchased a new position in Generation Bio in the second quarter worth $47,000. Finally, Shay Capital LLC bought a new position in Generation Bio in the third quarter valued at $64,000. 95.22% of the stock is owned by hedge funds and other institutional investors.

Generation Bio Price Performance

NASDAQ:GBIO opened at $5.34 on Friday. Generation Bio has a 1 year low of $3.00 and a 1 year high of $8.20. The stock’s fifty day moving average price is $5.51 and its two-hundred day moving average price is $5.70. The company has a market cap of $35.99 million, a P/E ratio of -0.57 and a beta of 2.05.

Generation Bio Company Profile

Generation Bio, Inc (NASDAQ: GBIO) is a clinical-stage genetic medicine company dedicated to developing ultra-long-term non-viral gene therapies for serious, chronic diseases. Headquartered in Cambridge, Massachusetts, Generation Bio focuses on harnessing its proprietary Gene Delivery System to deliver plasmid DNA payloads via lipid nanoparticles, enabling durable expression of therapeutic proteins in target tissues without the use of viral vectors.

The company’s lead approach is centered on a modular platform designed to address monogenic disorders and other chronic conditions that require continuous protein replacement or modulation.